{
    "nctId": "NCT04854005",
    "briefTitle": "Use of Sentinel Lymph Node Biopsy in Patients with Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation",
    "officialTitle": "Selective Use of ALND in N1 HR+/HER2- Breast Cancer Patients with 1 or 2 Positive Sentinel Lymph Nodes Undergoing Upfront Breast Surgery and Adjuvant Radiation: a Prospective Study",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 78,
    "primaryOutcomeMeasure": "evaluate rates of axillary lymph node dissection",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients aged \u226518 years with biopsy-proven invasive breast cancer\n* Patients with cTx, cT1, or cT2 tumors with palpable ipsilateral mobile adenopathy of level I/II axillary nodes with biopsy-proven (either by pre-operative biopsy or intraoperative frozen section) nodal metastasis (cN1) who are undergoing upfront surgery\n* Patients with tumors of the HR+/HER2- subtype, defined as:\n\n  1. HR+: Positive for estrogen receptor and/or progesterone receptor staining, indicated by \u22651% immunoreactive tumor nuclei\n  2. HER2-: Immunohistochemistry assay demonstrating no or faint staining in \u226410% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay\n\nExclusion Criteria:\n\n* Patients with prior ipsilateral breast cancer\n* Patients who are pregnant\n* Patients with stage IV disease at presentation\n* Patients with advanced regional disease (cN2/cN3)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}